Overview

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
0
Participant gender:
Female
Summary
This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. The anticipated time on study treatment is 3-12 months.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Carboplatin
Gemcitabine
Paclitaxel
Pertuzumab
Criteria
Inclusion Criteria:

- histologically confirmed ovarian, primary peritoneal, or fallopian tube cancer;

- only 1 previous regimen, which must be platinum-based;

- platinum-sensitive disease which is defined by a progression-free interval of greater
than 6 months after completion of platinum-based chemotherapy.

Exclusion Criteria:

- previous radiotherapy;

- previous treatment with an anti-cancer vaccine or any targeted therapy;

- major surgery or traumatic injury within 4 weeks of study;

- history or evidence of central nervous system metastases.